Tags : Qternmet XR

AstraZeneca’s Qternmet XR (dapagliflozin, saxagliptin, metformin hydrochloride) Receives FDA’s Approval

Shots: The approval is based on two P-III studies assessing the combination of dapagliflozin (5mg, 10mg) ,saxagliptin (5mg) and metformin in patients with inadequately controlled Type-2 diabetes for 24wks. The collective studies result demonstrated a reduction in HbA1c (average blood glucose levels) & increment in no. pf patients achieving HbA1c <7% Qternmet XR (qd, PO) […]Read More